Juno Therapeutics to take on the University of Pennsylvania in legal showdown over next-generation cancer therapy.
Juno Therapeutics, an oncology startup founded last month with $120m venture backing, is starting 2014 with a legal battle against the University of Pennsylvania over the rights to next generation cancer therapies. The dispute is over chimeric antigen receptors (CARs) which, as reported last month, are capable of reprogramming T-Cells, one of the body’s natural…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
